| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 118,697 | 102,660 | 78,335 | 48,118 |
| Selling, general and administrative | - | - | 84,995 | 57,910 |
| Research and development | - | - | 14,409 | 12,128 |
| Cost of sales | - | - | 5,211 | 3,242 |
| Total operating expenses | 133,226 | 124,844 | 104,615 | 73,280 |
| Loss from operations before other income (expense) | -14,529 | -22,184 | -26,280 | -25,162 |
| Interest income | 4,114 | 4,229 | 3,454 | 4,120 |
| Interest expense | 2,268 | 2,240 | 2,213 | 2,445 |
| Loss on debt extinguishment | 0 | 0 | - | - |
| Other income (expense), net | 98 | -145 | -81 | 67 |
| Total other income (expense), net | 1,944 | 1,844 | 1,160 | 1,742 |
| Net loss | -12,585 | -20,340 | -25,120 | -23,420 |
| Unrealized gain (loss) on marketable securities and cash equivalents | 250 | -46 | -94 | 522 |
| Comprehensive loss | -12,335 | -20,386 | -25,214 | -22,898 |
| Net loss per share - basic (usd per share) | -0.3 | -0.48 | -0.64 | -0.61 |
| Net loss per share - diluted (usd per share) | -0.3 | -0.48 | -0.64 | -0.61 |
| Weighted-average shares outstanding - diluted (in shares) | 42,607,717 | 42,360,452 | 39,345,359 | 38,381,968 |
| Weighted-average shares outstanding, basic (in shares) | 42,607,717 | 42,360,452 | 39,345,359 | 38,381,968 |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)